We are here ready to support Health Medicine with free home delivery.

Email Address

contact@megatropehgh.com

CONTACT US
Retatrutide 40mg Peptide Injection Pen (2 pens 20 mg each)
Retatrutide 40mg Peptide Injection Pen (2 pens 20 mg each) - Image 2
Retatrutide 40mg Peptide Injection Pen (2 pens 20 mg each) - Image 3
Retatrutide 40mg Peptide Injection Pen (2 pens 20 mg each) - Image 4
Retatrutide 40mg Peptide Injection Pen (2 pens 20 mg each) - Image 5
Retatrutide 40mg Peptide Injection Pen (2 pens 20 mg each) - Image 6
Retatrutide 40mg Peptide Injection Pen (2 pens 20 mg each) - Image 7

Retatrutide 40mg Peptide Injection Pen (2 pens 20 mg each)

Contact

Retatrutide 40mg Peptide Injection Pen (2 pens 20 mg each)

GIP, GLP-1 & Glucagon Triple Agonist

Key Product Characteristics

Triple Receptor Activity

Designed to activate GIP, GLP-1 and glucagon receptors as part of ongoing clinical research.

Subcutaneous Delivery

Pre-filled pen format designed for subcutaneous administration in clinical research settings.

Once-Weekly Research Format

Retatrutide is being investigated as a once-weekly subcutaneous treatment in clinical trials.

Product Features

  • Retatrutide 40 mg (2 pens 20 mg each)
  • 2 Pre-Filled Injection Pen
  • Subcutaneous Administration
  • Investigational Peptide Compound

Formula & Compound Information

Active Compound

Retatrutide (LY3437943)

Receptor Profile

GIP, GLP-1 and glucagon receptor agonist

Compound Type

Investigational peptide-based biologic

Product Specifications

Product Name

Retatrutide 40 mg (2 pens 20 mg each)

Presentation

Pre-Filled Injection Pen

Administration

Subcutaneous use only